The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02140541

Enrollment

130248

Registered

2014-05-16

Start date

2013-02-28

Completion date

2014-07-31

Last updated

2014-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma, Blood eosinophils, Sputum eosinophils, Clinical predictor, UK primary care, Global Initiative for Asthma (GINA)

Brief summary

To explore the relationship between blood eosinophil counts, asthma exacerbations and patient asthma control using a large primary care based research database

Detailed description

Sputum eosinophil levels have been shown to predict asthma exacerbation and inhaled corticosteroid (ICS) responsivenesss. Managing asthma based on sputum eosinophils leads to fewer exacerbations than management adhering to Global Initiative for Asthma (GINA) guidelines. However the use of sputum to measure eosinophil levels is expensive and impractical within a clinical setting. This study explores the use of blood-eosinophil levels as a clinical predictor for exacerbations and asthma control within a UK primary care dataset.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patient aged 12-80 at date of last eosinophil count * Asthma diagnosis at any time * Blood Eosinophil reading in patient record (numeric count expressed in µl) at least one year prior to last data extraction * Two years of continuous data

Exclusion criteria

* Any other chronic respiratory diseases * Eosinophil counts \>5000/µl (outliers)

Design outcomes

Primary

Measure	Time frame	Description
Exacerbations	1 year	Defined as: * American Thoracic Society / European Respiratory Society (ATS/ERS) task force definition: Asthma related hospital admissions OR accident and emergency (A&E) room attendance OR Use of acute oral steroids * Clinical definition: ATS/ERS definition including any GP consultations for lower respiratory related tract infections (LRTIs) treated with antibiotics
Asthma control	1 year	Defined as: * Risk domain asthma control: No Asthma-related hospital attendance, A&E attendance, out-patient department attendance, no prescriptions for acute oral steroids and no GP consultations for LRTIs treated with antibiotics * Overall asthma control: Risk domain asthma control definition, including average daily dose of ≤200mcg salbutamol

Countries

United Kingdom

Outcome results